Calcified Tissue International

, Volume 53, Issue 1, pp 17–20

A clinical trial on the effects of a combination of elcatonin (Carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women

Authors

  • M. Meschia
    • IIIrd Department, Obstetrics and GynaecologyUniversity of Milan
  • M. Brincat
    • Department of Obstetrics and GynaecologyUniversity of Malta
  • P. Barbacini
    • IIIrd Department, Obstetrics and GynaecologyUniversity of Milan
  • P. G. Crossignani
    • IIIrd Department, Obstetrics and GynaecologyUniversity of Milan
  • W. Albisetti
    • Department of OrthopaedicsUniversity of Milan
Clinical Investigations

DOI: 10.1007/BF01352009

Cite this article as:
Meschia, M., Brincat, M., Barbacini, P. et al. Calcif Tissue Int (1993) 53: 17. doi:10.1007/BF01352009

Summary

The study was carried out to determine the effect of a combination regimen of a small dose of calcitonin added to conjugated estrogens with medroxyprogesterone acetate on vertebral bone mass in early postmenopausal women. Comparisons were made with groups of women on calcitonin alone, on conjugated estrogens with medroxyprogesterone acetate alone, or on no treatment. The study was carried out over a 2-year period. The results of the study suggest that the combined regimen of calcitonin and estrogens increased vertebral bone mass in early postmenopausal women to a greater extent than calcitonin alone or estrogen alone. Increases in vertebral bone mass of 11.2% after 1 year and 9.2% after 2 years were demonstrated using the combined regimen. Both estrogens alone and calcitonin alone were, however, very effective in preventing rapid bone loss in the postmenopausal women studied.

Key words

Early postmenopauseVertebral bone massCombined regimenCalcitoninEstrogenOsteoporosis

Copyright information

© Springer-Verlag New York Inc. 1993